Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The MHC class II pathway is a critical process in adaptive immunity where antigen-presenting cells (APCs) display processed peptide antigens on their surface using Major Histocompatibility Complex class II (MHC-II) molecules. This presentation is essential for the activation of CD4+ T helper cells, which orchestrate downstream immune responses including B cell activation and antibody production. The pathway involves antigen uptake, processing into peptides within endosomes, loading onto MHC-II molecules (regulated by HLA-DM), and subsequent presentation to T cells. Defects in the pathway can lead to immunodeficiency or autoimmunity.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex Class II (MHC-II) Antigen Presentation Pathway (MHC-II Pathway).